SLS
What one share of SELLAS Life Sciences Group holds
Pharmaceutical Preparations
We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
SELLAS Life Sciences Group’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.21 |
|---|---|
| Cash and investments | $0.69 |
| Book value | $0.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$670.00 | $5.92 | −$578.94 | — | $132.26 |
| 2011 | — | −$316.09 | $1.46 | −$405.15 | — | $214.53 |
| 2012 | — | −$559.68 | — | −$335.67 | — | $334.73 |
| 2013 | — | −$850.26 | $3.55 | −$324.33 | — | $53.79 |
| 2014 | — | −$306.61 | $0.48 | −$359.55 | — | $338.67 |
| 2015 | — | −$411.57 | $0.99 | −$311.17 | — | −$75.73 |
| 2016 | — | −$933.13 | $0.32 | −$625.71 | — | −$196.97 |
| 2017 | — | −$521.91 | — | −$234.77 | — | — |
| 2018 | — | −$157.72 | — | −$116.32 | — | $11.91 |
| 2019 | — | −$10.92 | — | −$6.90 | — | $1.20 |
| 2020 | $0.24 | −$2.11 | — | −$1.31 | — | $1.96 |
| 2021 | $0.49 | −$1.34 | — | −$1.68 | — | $1.28 |
| 2022 | $0.05 | −$2.13 | — | −$1.23 | — | $0.23 |
| 2023 | $0.00 | −$1.34 | — | −$1.13 | — | −$0.25 |
| 2024 | — | −$0.50 | — | −$0.58 | — | $0.13 |
| 2025 | — | −$0.25 | — | −$0.26 | — | $0.46 |